AstraZeneca to Pay $11 Million to Settle Toprol-XL Antitrust Claims

AstraZeneca Pharmaceuticals agreed to pay $11 million to settle claims by a proposed class of indirect purchasers of hypertension drug Toprol-XL that the drugmaker used sham patent litigation to prolong a monopoly on the drug by delaying generic versions.
Law360